Review





Similar Products

human hcc cell lines hepg2  (ATCC)
99
ATCC human hcc cell lines hepg2
Human Hcc Cell Lines Hepg2, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human hcc cell lines hepg2/product/ATCC
Average 99 stars, based on 1 article reviews
human hcc cell lines hepg2 - by Bioz Stars, 2026-02
99/100 stars
  Buy from Supplier
human hcc cell line hepg2  (ATCC)
99
ATCC human hcc cell line hepg2
Antitumor effects of SIT and combined treatment on HCC cells. <t>HepG2</t> cells (A) and Hepa1–6 cells (B) were administrated SIT, sorafenib, and sorafenib + SIT at serial concentrations, and Cell Counting Kit-8 (CCK-8) assays were used to determine the cell viability. HepG2 cells (C) and Hepa1–6 cells (D) were treated with SIT (2 μM), sorafenib (10 μM) or a combination of both, and cell proliferation was evaluated using the 5-ethynyl-29-deoxyuridine (EdU) assay. HepG2 cells (E) and Hepa1–6 cells (F) were treated with SIT (2 μM), sorafenib (10 μM) or a combination of both, and cell apoptosis induction was evaluated using flow cytometry. Hepa1–6 cells (G) were treated with SIT (2 μM), sorafenib (10 μM) or a combination of both, and vasculogenic mimicry (VM) formation was evaluated in three-dimensional culture. Data were presented as mean ± SEM, n = 3, One-way ANOVA. * p < .05; ** p < .01; *** p < .001; and **** p < .0001.
Human Hcc Cell Line Hepg2, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human hcc cell line hepg2/product/ATCC
Average 99 stars, based on 1 article reviews
human hcc cell line hepg2 - by Bioz Stars, 2026-02
99/100 stars
  Buy from Supplier
isolation 132 human hcc hepg2 cell lines  (ATCC)
99
ATCC isolation 132 human hcc hepg2 cell lines
Antitumor effects of SIT and combined treatment on HCC cells. <t>HepG2</t> cells (A) and Hepa1–6 cells (B) were administrated SIT, sorafenib, and sorafenib + SIT at serial concentrations, and Cell Counting Kit-8 (CCK-8) assays were used to determine the cell viability. HepG2 cells (C) and Hepa1–6 cells (D) were treated with SIT (2 μM), sorafenib (10 μM) or a combination of both, and cell proliferation was evaluated using the 5-ethynyl-29-deoxyuridine (EdU) assay. HepG2 cells (E) and Hepa1–6 cells (F) were treated with SIT (2 μM), sorafenib (10 μM) or a combination of both, and cell apoptosis induction was evaluated using flow cytometry. Hepa1–6 cells (G) were treated with SIT (2 μM), sorafenib (10 μM) or a combination of both, and vasculogenic mimicry (VM) formation was evaluated in three-dimensional culture. Data were presented as mean ± SEM, n = 3, One-way ANOVA. * p < .05; ** p < .01; *** p < .001; and **** p < .0001.
Isolation 132 Human Hcc Hepg2 Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/isolation 132 human hcc hepg2 cell lines/product/ATCC
Average 99 stars, based on 1 article reviews
isolation 132 human hcc hepg2 cell lines - by Bioz Stars, 2026-02
99/100 stars
  Buy from Supplier

Image Search Results


Antitumor effects of SIT and combined treatment on HCC cells. HepG2 cells (A) and Hepa1–6 cells (B) were administrated SIT, sorafenib, and sorafenib + SIT at serial concentrations, and Cell Counting Kit-8 (CCK-8) assays were used to determine the cell viability. HepG2 cells (C) and Hepa1–6 cells (D) were treated with SIT (2 μM), sorafenib (10 μM) or a combination of both, and cell proliferation was evaluated using the 5-ethynyl-29-deoxyuridine (EdU) assay. HepG2 cells (E) and Hepa1–6 cells (F) were treated with SIT (2 μM), sorafenib (10 μM) or a combination of both, and cell apoptosis induction was evaluated using flow cytometry. Hepa1–6 cells (G) were treated with SIT (2 μM), sorafenib (10 μM) or a combination of both, and vasculogenic mimicry (VM) formation was evaluated in three-dimensional culture. Data were presented as mean ± SEM, n = 3, One-way ANOVA. * p < .05; ** p < .01; *** p < .001; and **** p < .0001.

Journal: Translational Oncology

Article Title: β-Sitosterol enhances the anti-tumor efficacy of sorafenib in hepatocellular carcinoma via the FXR/LXR/ SREBP1/ FASN pathway

doi: 10.1016/j.tranon.2025.102610

Figure Lengend Snippet: Antitumor effects of SIT and combined treatment on HCC cells. HepG2 cells (A) and Hepa1–6 cells (B) were administrated SIT, sorafenib, and sorafenib + SIT at serial concentrations, and Cell Counting Kit-8 (CCK-8) assays were used to determine the cell viability. HepG2 cells (C) and Hepa1–6 cells (D) were treated with SIT (2 μM), sorafenib (10 μM) or a combination of both, and cell proliferation was evaluated using the 5-ethynyl-29-deoxyuridine (EdU) assay. HepG2 cells (E) and Hepa1–6 cells (F) were treated with SIT (2 μM), sorafenib (10 μM) or a combination of both, and cell apoptosis induction was evaluated using flow cytometry. Hepa1–6 cells (G) were treated with SIT (2 μM), sorafenib (10 μM) or a combination of both, and vasculogenic mimicry (VM) formation was evaluated in three-dimensional culture. Data were presented as mean ± SEM, n = 3, One-way ANOVA. * p < .05; ** p < .01; *** p < .001; and **** p < .0001.

Article Snippet: The human HCC cell line HepG2 and the murine HCC cell line Hepa1–6 was purchased from the American Type Culture Collection.

Techniques: Cell Counting, CCK-8 Assay, EdU Assay, Flow Cytometry